Hyperliquid Strategies Inc. (PURR) - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarter and six months ended December 31, 2025. Hyperliquid Strategies Inc. (HSI) is a cryptocurrency treasury company focused on accumulating and staking HYPE tokens, the native asset of the Hyperliquid Layer-1 blockchain. The company was formed via a reverse recapitalization and business combination with Sonnet BioTherapeutics Holdings, Inc. (Sonnet) and Rorschach I LLC, closing on December 2, 2025. HSI operates as a single segment and is classified as an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Total Revenue | $0.5 million | $0.5 million |
| Net Loss | $(304.5) million | $(317.9) million |
| Net Loss Per Share (Basic/Diluted) | $(7.43) | $(15.50) |
| Cash and Cash Equivalents | $281.9 million | $281.9 million |
| HYPE Digital Assets (Fair Value) | $327.6 million | $327.6 million |
| Total Assets | $616.6 million | $616.6 million |
| Total Liabilities | $26.9 million | $26.9 million |
| Stockholders' Equity | $589.8 million | $589.8 million |
Operating Expenses: Total operating expenses were $288.0 million for the quarter and $301.4 million for the six months. This includes significant non-cash charges: an unrealized loss on HYPE digital assets of $93.2 million, a loss on HYPE contribution commitment of $155.8 million (quarter) / $169.2 million (six months), and an IPR&D write-off from the Sonnet acquisition of $35.6 million.
Material Changes vs. Prior Period
- Reverse Recapitalization: The company underwent a reverse recapitalization with Rorschach and acquired Sonnet. Prior to the closing on December 2, 2025, the company had no material assets or operations. The balance sheet as of June 30, 2025, showed zero assets and a deficit of $0.6 million.
- Capital Raise: The company raised approximately $880.4 million in aggregate fair value (cash and HYPE tokens) through a Closing PIPE and contributions. This resulted in a cash balance of $281.9 million and HYPE holdings valued at $327.6 million.
- Valuation Volatility: The 12.5 million HYPE tokens contributed at closing were valued at $580.5 million based on the commitment price but were remeasured at $411.3 million at the closing date, triggering a $169.2 million loss on commitment. Further unrealized losses of $93.2 million were recognized due to price declines by period end.
- Acquisition Costs: The acquisition of Sonnet was accounted for as an asset acquisition, resulting in a $35.6 million write-off of in-process research and development (IPR&D) with no alternative future use.
Outlook, Risks, and Management Commentary
- Liquidity: Management states that the substantial doubt regarding the company's ability to continue as a going concern has been alleviated by the capital raised in the Closing PIPE and the entry into a $1.0 billion Equity Facility with Chardan Capital Markets LLC. Management expects existing resources to fund operations for the next 12 months.
- Strategy: The primary focus remains building a treasury of HYPE tokens and generating staking rewards. The company also continues Sonnet's biotech operations as a subsidiary.
- Stock Repurchase: The Board authorized a $30 million stock repurchase program. As of December 31, 2025, the company repurchased 2.94 million shares for approximately $10.1 million.
- Risks: The company's financial condition is heavily dependent on the market price and liquidity of HYPE tokens, which are subject to extreme volatility. The company also faces risks related to the success of the Hyperliquid blockchain and the potential inability to secure additional working capital if needed.
- Contingencies: The company issued Contingent Value Rights (CVRs) to former Sonnet shareholders, payable upon the monetization of legacy assets within three years. The fair value is currently considered nominal.
Key Facts for Investor Verification
- HYPE Token Valuation: Verify the current market price of HYPE tokens, as the company's asset base and net income are highly sensitive to price fluctuations (unrealized losses of $93.2M recognized in Q4).
- Going Concern Status: Confirm that the $1.0 billion Equity Facility remains available and that no additional funding is required to meet obligations beyond the 12-month forecast.
- Sonnet Legacy Assets: Monitor the status of Sonnet's biotech assets and the likelihood of a "Company Legacy Transaction" that would trigger payments on the Contingent Value Rights.
- Staking Yield: Review the actual staking rewards generated versus the $0.5 million recognized, noting that rewards are inversely proportional to the total network stake.
- Equity Dilution: Assess the impact of outstanding warrants (approx. 29.8 million) and the potential issuance of shares under the Equity Facility on future earnings per share.